prostate cancer - Search News

Order byBest matchMost fresh

Former President Biden announces prostate cancer diagnosis

Should Men Screen for Prostate Cancer? Biden Diagnosis Reignites Debate

Former President Joe Biden’s diagnosis of an aggressive, stage-4 prostate cancer has reignited a long-simmering medical debate: When should men get screened for prostate cancer? For decades, doctors have wrestled with how often to screen men for the disease and when to start and stop.

· 7h · on MSN

· 2d · on MSN

Biden's prostate cancer diagnosis raises questions about screening and how the disease spreads

The New Yorker · 1h

What to Make of Biden’s Prostate Cancer Diagnosis

A hospice nurse’s hope for Biden: ‘Show us how to live well with the time we have’

Cancer touches almost everyone eventually.

· 5h

· 1d

House Republicans to zero in on autopen use as part of investigation into Biden's health

· 1d

Denial Is a Bad Strategy if You’re an Aging President

Democrats may require 2028 contenders to release full health information after disastrous Biden campaign

Some Democrats are discussing plans to require 2028 contenders to release their full health information after the disastrous campaign of former President Joe Biden.

· 7h

· 14h

Biden’s Cancer and a Lawmaker’s Death Keep Focus on Democrats’ Age Problem

· 8h

Where Does Joe Biden Live? Examining the Former President’s Homes

8hon MSN

The best diet to lower your risk of prostate cancer, according to experts

Research indicates that certain foods—specifically meat and dairy—could increase the risk of prostate cancer, says Martha Silva, RD, LDN, oncolo

2don MSN

What we do and don’t know about Biden’s prostate cancer diagnosis

The announcement Sunday that former President Joe Biden was diagnosed with advanced prostate cancer has some people wondering how the disease could have been missed.

MedPage Today9h

FDA Panel Votes Against Broad Talazoparib-Enzalutamide Label in Prostate Cancer

An FDA advisory committee on Wednesday unanimously voted against recommending approval of the PARP inhibitor talazoparib (Talzenna) plus enzalutamide (Xtandi) for all patients with metastatic castration-resistant prostate cancer (mCRPC).